Lions New HGH Fragment

[Random]

Guys, check out Lions new hgh fragment...does anyone know what dose one should use this at? thanks CD

[Triposinator]

I'd suggest you ask Lion.

Guys, check out Lions new hgh fragment...does anyone know what dose one should use this at? thanks CD

[Random]

I did, he said he could not provide that information

[FranKieC]

I believe logan ran HGH Frag a couple months back..If he is still here try asking him what dose he took

[HORSE~]

Post # eight lion says how he will be running it....

hGH FRAGMENT 177-191

[Random]

Thanks horse2006....!

[Random]

Also..is this meant for intra muscular or sub q???

[FranKieC]

Also..is this meant for intra muscular or sub q???

Sub Q

[Mike Dura]

Before buying anything from this or any other bodybuilding forum, it's a good policy to check references. Just ask.

Guys, check out Lions new hgh fragment...does anyone know what dose one should use this at? thanks CD

[Triposinator]

Sooooo does that response mean anything to you?

Just my opinion, if he can't provide BASIC info like that, try another question, for example, " can you send me lab results on your product?"

Fvcking A man wake up....if the guy won't stand behind his product why the fvck would you inject it into your body?

I did, he said he could not provide that information

[elite2kr]

Inovative Research has had this for ages.... Plus lion overcharges on his crap!

[Random]

Fvcking A man wake up....if the guy won't stand behind his product why the fvck would you inject it into your body?

Whoever said i would be injecting it? I will not be using it FYI

[cfiler]

Sooooo does that response mean anything to you?

Just my opinion, if he can't provide BASIC info like that, try another question, for example, " can you send me lab results on your product?"

Fvcking A man wake up....if the guy won't stand behind his product why the fvck would you inject it into your body?

It's a research chemical. Think about that for a second. That means that you buy it to do your own research.

I have never had any problems with products from AR-R . My "lab rat" especially loves their clen .

[RUI-Products]

Basicly there are legal issues that keep me from answer basicly all dosing questions. I stand behind all our products. I use them in my own research.

[RUI-Products]

Here is a piece of a study about the fragment. The entire study can be found at http://endo.endojournals.org/cgi/co...ull/142/12/5182




It is well established that hGH is a lipolytic hormone (15), but the exact mechanisms used are still unclear. In this paper we present data that suggest that hGH and its lipolytic fragment (AOD9604) induce their chronic in vivo actions on lipolysis in part by modulating the expression of the ß3-AR. Human GH has been shown to affect the in vivo expression and function of ß-ARs in vivo in sheep (16). Data presented in this paper indicate that chronic administration of hGH influences expression of the ß3-AR in adipose tissue in the ob/ob mouse. In brown adipose tissue (BAT), these compounds also increase expression of ß3-AR expression in the lean C57BL/6J mouse. The increase in expression induced by chronic hGH or AOD9604 treatment correlated with the decrease in adipose tissue mass. We therefore hypothesize that treatment with either hGH or AOD9604 enhances ß3-AR expression, which has been observed in murine 3T3-F442A and human SK-N-MC cells in vitro (11).

Both AOD9604 and, to a greater extent, hGH increase body weight in lean mice, compared with saline-treated animals. This is in the absence of an increase in fat mass, which suggests an increase in lean body mass occurs with these compounds. This supports previous work with hGH in rodents and humans (17). Both compounds have also been previously shown to reduce body weight and adiposity in obese mice (11). The effects of hGH and AOD9604 occur without significant changes to caloric intake. It has been reported that hGH increases, reduces, or does not change food intake in which the differences are attributed to variations in hGH preparations, concentrations, and animals used between different laboratories.

The effects of hGH and AOD9604 on fat metabolism may be mediated by an alteration in the expression of a lipolytic/antilipogenic gene. The &#223;3-AR is a major lipolytic receptor identified in rodent fat cells (18) that mediates its effects through G protein coupling to adenylate cyclase, generation of cAMP, and stimulation of PKA (19). This enzyme then phosphorylates proteins in the lipolytic cascade, including hormone-sensitive lipase (20). In BAT, the &#223;3-AR stimulates uncoupling of the electron transport chain, enhancing the ability of mitochondria to generate heat in preference to ATP through the dissipation of the electron gradient (21). Mice that lack this receptor have lower rates of resting energy expenditure (0.0041 vs. 0.0047 kcal/min, P < 0.02) and lower rates of fat oxidation (0.00019 vs. 0.00030 g/min, P < 0.02) than control mice (data not shown).

AOD9604 and hGH appear to act in a similar manner to induce their effects on body weight regulation and adipose tissue mass in vivo. However, in vitro studies have demonstrated a number of differences suggesting that the two compounds operate via unique signaling pathways to control the regulation of the &#223;3-AR. These studies suggested that AOD9604 had no interaction with the &#223;3-AR or hGH receptors (11).

In lean animals, neither AOD9604 nor hGH had any effect on epididymal white adipose tissue mass or expression of &#223;3-AR RNA, indicating that in lean animals, this fat tissue is not a major target for these drugs in this study. In contrast, the mass of BAT in lean animals was reduced by both hGH and AOD9604, and &#223;3-AR RNA expression was increased by both these compounds. This could possibly suggest that the increased expression of &#223;3-ARs in brown adipocytes sensitizes catecholamines to dissipate heat.

In ob/ob mice, both AOD9604 and hGH reduced both white and brown adipose tissue mass and increased &#223;3-AR RNA expression. This suggested that an elevation in &#223;3-AR RNA expression is associated with increased fat metabolism and a reduction in the fat tissue mass in the ob/ob mouse model. Obese mice have lower levels of &#223;3-AR expression in their adipose tissues than lean mice, shown in this study and others (14). The ability of AOD9604 and hGH to increase the level of &#223;3-AR RNA expression in obese mice to a level that is comparable to those in lean mice is an exciting finding. However, it must also be considered that both hGH and AOD9604 may influence the expression of other members of the adrenergic pathway, such as the &#223;1-ARs, hormonesensitive lipase, and signaling proteins, which are all expressed in adipose tissue and associated with lipolysis. The importance of the change in &#223;3-AR expression with AOD9604 and hGH in humans is not established and will depend on the use of potent and selective &#223;3-AR agonists that are active at the human receptor.

From this study it appears that the &#223;3-AR is an important contributor to the effects observed on body weight in obese mice treated with AOD9604 and hGH. To determine whether the &#223;3-AR is partly responsible for this effect, we examined the effects of AOD9604 and hGH in the &#223;3-KO mouse. The &#223;3-KO mouse is not grossly obese, but female mice have increased fat depots (21) and the mice do develop late-onset obesity (Summers, R. J., personal communication). AOD9604 and hGH increased body mass and decreased BAT mass in the WT strain but had no effect in the KO animals. In WT mice, plasma glycerol was increased in response to AOD9604 and hGH treatment (4 wk). However, in the KO mice, only hGH resulted in increased levels of glycerol in the KO mice, and this effect was significantly less than that observed in the WT mice. This suggests that the regulation of the &#223;3-AR is essential in the ability of AOD9604 and hGH to mediate chronic effects on lipolysis and fat mass reduction.

The effect of AOD9604 and hGH on &#223;3-ARs in adipose tissue is believed to be a direct action of these compounds and not an effect secondary to the fat metabolism, given that both AOD9604 and hGH can influence &#223;3-AR expression and function in a nonadipocyte human cell line (11). Hence, the &#223;3-AR appears to be necessary for the chronic effectiveness of AOD9604 on lipolysis in BAT.

The acute effect of AOD9604 and BRL37344 (a &#223;3-AR agonist) on energy expenditure and substrate oxidation rates in WT and KO mice was also assessed. KO animals had lower energy expenditure, lower fat oxidation, and increased glucose oxidation, compared with the WT controls (data not shown). Injection of WT mice with a single dose of BRL37344 or AOD9604 increased energy expenditure and fat oxidation and decreased glucose oxidation. In the KO animals, BRL37344 failed to elicit any response in these metabolic parameters, clearly demonstrating that its effects are mediated exclusively through the &#223;3-AR. AOD9604 did elicit a response in the KO mice, increasing fat oxidation and energy expenditure, although the response was not as great as in WT mice, suggesting that &#223;3-ARs are not responsible for the acute biological response of AOD9604 on lipid metabolism. This is consistent with our previous findings in which AOD9604 was shown not to bind to the &#223;3-AR (11). The size and duration of the metabolic responses to AOD9604 in the &#223;3-AR KO animals was different from that observed in the control wild-type mice. The response was more rapid, shorter in duration, and greater in peak response. This may be because the KO animals are more acutely sensitive to lipolytic agents, a compensation for the ablation of the major lipolytic receptor.

These findings suggest that the acute effects of AOD9604 are quite different from the chronic effects. Enhanced &#223;3-AR expression appears to play a major role in the chronic effectiveness of the compound in terms of fat metabolism and weight loss. The acute effects observed in this study confirm that the &#223;3-AR is not the sole mediator of this action. The increase in &#223;3-AR expression in response to hGH and AOD9604 would permit enhanced lipolytic sensitivity. Identification of the components of the intracellular pathway(s) and effector(s) activated by AOD9604 are currently being investigated. The results presented in this paper suggest that the effectiveness of AOD9604 and hGH may partly rely on their ability to increase levels of &#223;3-AR RNA expression in models of obesity in which the numbers of the lipolytic receptor are low. These unique properties may give AOD9604 an advantage over other lipolytic agonists such as adrenergic agents and hGH, which exhibit undesirable side effects when administered chronically (22).
__________________

[Random]

have never had any problems with products from AR-R

Agreed

[cantspeak]

200mcg daily dose for 30 - 6months depending on how much you wanna spend ithink the longer the better like GH